SEC Form 4 · accession 0001144204-19-002698
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Mayne Pharma Group Ltd
10% Owner
Mayne Pharma International Pty Ltd
10% Owner
Mayne Pharma Ventures Pty Ltd
10% Owner
Period of report
Jan 15, 2019
Accepted (ET)
Jan 24, 2019 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 15, 2019 | J | 362,121 | $0.00 | A | 198,653,051 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 15, 2019, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 362,121 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock.
- F2These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.